Aclarion Adds to Strong Patent Portfolio with Notice of Allowance for New U.S. Patent Application Addressing Key Pain Indicator Biomarker
02 December 2022 - 01:41AM
via NewMediaWire -- Aclarion,
Inc.,
(“Aclarion” or the “Company”) (Nasdaq: ACON,
ACONW), a healthcare technology company that is leveraging
biomarkers and proprietary augmented intelligence algorithms to
help physicians identify the location of chronic low back pain,
announced today that it has received a Notice of Allowance for its
US Patent Application 16/224,590 titled “Magnetic Resonance
Spectroscopy System and Method for Diagnosing Pain or Infection
Associated with Propionic Acid”.
Conventional imaging (lumbar MRI) for Chronic Low
Back Pain offers important structural information but struggles to
identify the actual source of pain. Aclarion’s Nociscan
solution is the first evidence-supported SaaS platform to
noninvasively help physicians distinguish between painful and
nonpainful discs in the lumbar spine. Nociscan objectively
quantifies chemical biomarkers demonstrated to be associated with
disc pain. Biomarker data is entered into proprietary algorithms to
highlight if a disc may be a source of pain. When used with other
diagnostic tools, Nociscan provides critical insights into the
location of a patient’s low back pain, giving physicians clarity to
optimize treatment strategies.
The patent application 16/224,590 titled “Magnetic
Resonance Spectroscopy System and Method for Diagnosing Pain or
Infection Associated with Propionic Acid” expands the Aclarion
patent portfolio to broadly cover using MRS to identify
Propionic Acid (PA), a biomarker that the literature suggests may
be indicative of bacterial infection in a disc. This information
may prove critical in supporting the optimal treatment of low back
pain when infection is the underlying cause of pain. In these
cases, effective treatment with antibiotic therapy alone may
eliminate the need for surgical intervention.
"The mission of Aclarion is to give physicians
better data so they can make better decisions about the care of
their patients,” says Brent Ness, CEO. “We are committed to leading
with compelling clinical and economic evidence. The foundation of
our leadership is our Nociscan product and the patent portfolio on
which it is built. Allowance of this patent strengthens our
competitive moat and gives us the opportunity to advance our
mission by exploring whether Nociscan can help physicians address
the critical diagnostic decision of treating a patient with
antibiotics or surgical intervention.”
The Aclarion patent portfolio now includes 22 U.S.
patents, 17 foreign patents, 5 pending U.S. patent applications,
and 7 pending foreign patent applications, including patents and
patent applications exclusively licensed from Regents of the
University of California. About Aclarion, Inc.
Aclarion is a healthcare technology company that
leverages Magnetic Resonance Spectroscopy (“MRS”), proprietary
signal processing techniques, biomarkers, and augmented
intelligence algorithms to optimize clinical treatments. The
Company is first addressing the chronic low back pain market with
Nociscan, the first, evidence-supported, SaaS platform to
noninvasively help physicians distinguish between painful and
nonpainful discs in the lumbar spine. Through a cloud connection,
Nociscan receives magnetic resonance spectroscopy (MRS) data from
an MRI machine for each lumbar disc being evaluated. In the cloud,
proprietary signal processing techniques extract and quantify
chemical biomarkers demonstrated to be associated with disc pain.
Biomarker data is entered into proprietary algorithms to indicate
if a disc may be a source of pain. When used with other diagnostic
tools, Nociscan provides critical insights into the location of a
patient’s low back pain, giving physicians clarity to optimize
treatment strategies. For more information, please
visit www.aclarion.com.
Forward Looking Statements
This press release contains forward-looking
statements within the meaning of the Private Securities Litigation
Reform Act of 1995, Section 27A of the Securities Act of 1933 and
Section 21E of the Securities Exchange Act of 1934 about the
Company's current expectations about future results, performance,
prospects and opportunities. Statements that are not historical
facts, such as "anticipates," "believes" and "expects" or similar
expressions, are forward-looking statements. These forward-looking
statements are based on the current plans and expectations of
management and are subject to a number of uncertainties and risks
that could significantly affect the Company's current plans and
expectations, as well as future results of operations and financial
condition. These and other risks and uncertainties are discussed
more fully in our filings with the Securities and Exchange
Commission. Readers are encouraged to review the section titled
"Risk Factors" in the Company's Prospectus dated April 21, 2022, as
filed with the Securities and Exchange Commission on April 25, 2022
under Rule 424(b)(4), as well as other disclosures contained in the
Prospectus and subsequent filings made with the Securities and
Exchange Commission. Forward-looking statements contained in this
announcement are made as of this date and the Company undertakes no
obligation to publicly update or revise any forward-looking
statements, whether as a result of new information, future events
or otherwise.
Investor Contacts:Kirin M. SmithPCG
Advisory, Inc.646.823.8656ksmith@pcgadvisory.com
Media Contacts:Jodi LambertiSPRIG
Consulting612.812.7477jodi@sprigconsulting.com
Aclarion (NASDAQ:ACON)
Historical Stock Chart
From Feb 2024 to Mar 2024
Aclarion (NASDAQ:ACON)
Historical Stock Chart
From Mar 2023 to Mar 2024